Abstract Number: 0256 • ACR Convergence 2021
Consensus Approach to a Treat to Target Strategy in Juvenile Idiopathic Arthritis Care: Report from the 2020 Pediatric Rheumatology Care and Outcomes Improvement Network Consensus Conference
Background/Purpose: Treat to target (T2T) is a strategy of adjusting treatment until a therapeutic target is reached. There is growing evidence supporting the use and…Abstract Number: 0658 • ACR Convergence 2021
ACCORD: A Novel Rheumatology Transition Clinic Structure for Adolescent and Young Adult Patients with Childhood Onset Rheumatic Disease
Background/Purpose: The transition of health care from Pediatric to Adult providers for adolescents and young adults with childhood onset rheumatic disease continues to be associated…Abstract Number: 0792 • ACR Convergence 2021
Remission Rates of Patients with Rheumatoid Arthritis in a Tertiary Care
Background/Purpose: The main goal of treatment for patients (pts.) with rheumatoid arthritis (RA) is to achieve remission, in order to both, preserve physical function and…Abstract Number: 1258 • ACR Convergence 2021
Measurement of Specific Organ Domains in Lupus Randomised Controlled Trials
Background/Purpose: Randomised controlled trials (RCTs) in SLE typically adopt composite responder definitions as primary efficacy endpoints, however outcomes within individual organ domains are also important…Abstract Number: 1809 • ACR Convergence 2021
Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis
Background/Purpose: Enthesitis (inflammation where the tendon, ligament, or joint capsule insert into the bone) has been associated with higher disease activity and reduced quality of…Abstract Number: 0320 • ACR Convergence 2021
Performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), an Adjusted ESSDAI Score, in Two Randomised Clinical Trials in Patients with Primary Sjögren’s Syndrome
Background/Purpose: Recent randomised controlled trials (RCTs) in primary Sjögren’s syndrome (pSS) failed to show clinical efficacy.1-3 Several RCTs used the EULAR Sjögren’s Syndrome Disease Activity…Abstract Number: 0674 • ACR Convergence 2021
A Behavioral Intervention to Improve Gout Outcomes in African Americans with Gout: A 12-month Multicenter, Randomized Controlled Trial
Background/Purpose: Gout outcomes and severity are worst in African Americans compared to Caucasians with gout. Racial Disparities in gout are well-described. Few or no data…Abstract Number: 0814 • ACR Convergence 2021
Patient Characteristics, Efficacy, and Treatment Patterns of Tofacitinib Monotherapy in Patients with RA: Contextualization of Randomized Controlled Trial Results with Real-world Data
Background/Purpose: Randomized controlled trials (RCTs) have long been considered the gold standard for clinical research, but can be complemented with real-world data (RWD) to further…Abstract Number: 1259 • ACR Convergence 2021
Association of SLE Responder Index (SRI) Attainment and Long-term Clinical Outcomes
Background/Purpose: The SLE Responder Index (SRI) is a composite responder definition employed as a clinical trial endpoint in SLE. Despite its widespread adoption, recent discrepant…Abstract Number: 1863 • ACR Convergence 2021
Consistent Efficacy with Apremilast in Men and Women to Treat Oral Ulcers Associated with Behçet’s Syndrome: Results from Phase 3 Researching Oral Apremilast Safety and Efficacy in Behçet’s Disease (RELIEF) Study
Background/Purpose: Painful, recurring oral ulcers (OU) associated with Behçet’s syndrome negatively affect quality of life (QoL). Differences across sexes were reported in the frequency of…Abstract Number: 0336 • ACR Convergence 2021
The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE
Background/Purpose: The comparative clinical utility of various diagnostic tests to aid the differential diagnosis of SLE is unclear. We compare the outcomes of testing with…Abstract Number: 0690 • ACR Convergence 2021
Impact of Achieving 2016 ACR/EULAR Response Criteria on Patient Centered Outcome Measures in Myositis
Background/Purpose: The 2016 ACR/EULAR Myositis Response Criteria represent a composite measure that is increasingly being used as a primary end point in myositis clinical trials.…Abstract Number: 0845 • ACR Convergence 2021
A Non-Interventional Prospective Observational Study of Treatment with Etanercept Biosimilar (SB4) in Rheumatoid Arthritis in Real Life Clinical Practice; Interim Analysis of the ‘BENEFICIAL’ Study
Background/Purpose: SB4 is an etanercept biosimilar that obtained EU regulatory approval in 2016, and became available in Greece in 2018. Due to lack of published…Abstract Number: 1261 • ACR Convergence 2021
The Impact of Remission and Low Disease Activity Attainment on Health-related Quality of Life in Two Phase III Clinical Trials of Belimumab in Systemic Lupus Erythematosus
Background/Purpose: Health-related quality of life (HRQoL) is considered one of the most important outcomes in clinical trials of systemic lupus erythematosus (SLE), along with reduction…Abstract Number: 1879 • ACR Convergence 2021
Delayed Diagnosis of IgG4 Related Disease Is Associated with Worse Outcome: A Retrospective, Real-life Observational Study
Background/Purpose: The purpose of this study was to characterize clinical and pathological features as well as disease outcome of an Israeli incident cohort of patients…
- 1
- 2
- 3
- …
- 23
- Next Page »